-
Journal of the Neurological Sciences Jan 2022
Review
Topics: Disease Progression; Humans; Parkinson Disease
PubMed: 34923333
DOI: 10.1016/j.jns.2021.120082 -
International Journal of Clinical... May 2015
Topics: Disease Progression; Early Diagnosis; Humans; Pulmonary Disease, Chronic Obstructive
PubMed: 25913913
DOI: 10.1111/ijcp.12622 -
Arthritis & Rheumatology (Hoboken, N.J.) May 2016
Topics: Disease Progression; Extracellular Matrix; Fibrosis; Humans
PubMed: 26748676
DOI: 10.1002/art.39569 -
The Lancet. Neurology Dec 2017
Topics: Alzheimer Disease; Biomarkers; Disease Progression; Humans
PubMed: 29165249
DOI: 10.1016/S1474-4422(17)30376-9 -
Heart Rhythm Feb 2016
Topics: Atrial Fibrillation; Disease Progression; Humans; Tachycardia, Paroxysmal
PubMed: 26545938
DOI: 10.1016/j.hrthm.2015.11.002 -
Journal of Neurology, Neurosurgery, and... Nov 2017
Topics: Amyotrophic Lateral Sclerosis; Disease Progression; Humans; Magnetic Resonance Imaging; Motor Neuron Disease
PubMed: 28754667
DOI: 10.1136/jnnp-2017-316001 -
Arthroscopy : the Journal of... Jan 2019Defining and understanding natural history data for any disease is paramount to developing effective treatment strategies: degenerative rotator cuff disease is no...
Defining and understanding natural history data for any disease is paramount to developing effective treatment strategies: degenerative rotator cuff disease is no different. The natural history defines disease progression without treatment or intervention. Given the persistent variable indications for surgical intervention for painful rotator cuff tears, a more thorough understanding of the rate of progression of full-thickness rotator cuff tears can help to refine surgical indications and potentially define the risks of nonoperative treatment. This systematic review synthesizes existing literature and takes the surgeon one step closer to understanding the rates of tear progression for untreated tears-one small step.
Topics: Disease Progression; Humans; Lacerations; Rotator Cuff; Rotator Cuff Injuries; Rupture
PubMed: 30611354
DOI: 10.1016/j.arthro.2018.09.010 -
Journal of Biopharmaceutical Statistics Mar 2021In traditional dose-finding studies, dose-limiting toxicity (DLT) is determined within a fixed time observation window where DLT is often defined as a binary outcome. In...
In traditional dose-finding studies, dose-limiting toxicity (DLT) is determined within a fixed time observation window where DLT is often defined as a binary outcome. In the setting of oncology dose-finding trials, often patients in advanced stage of diseases are enrolled. Therefore, disease progression may occur within the DLT observation window leading to treatment discontinuation and rendering the patient unevaluable for DLT assessment. As a result, additional patients have to be enrolled, increasing the sample size. We propose and compare several practical approaches for handling disease progression which occurs within the DLT observation window, while in the framework of the time-to-event continual reassessment method (TITE-CRM) which allows using partial observations. The approaches differ on the way they define an evaluable patient and in the way incomplete observations are included. The practical approaches, which we call strategies A, B and C, are illustrated and contrasted in the context of a single simulated trial, and compared via simulations under various scenarios of dose-progression relationship, in the setting of advanced soft-tissue sarcoma.
Topics: Clinical Trials as Topic; Computer Simulation; Disease Progression; Humans; Research Design
PubMed: 32931360
DOI: 10.1080/10543406.2020.1814796 -
British Journal of Pharmacology Nov 2023In a physiological context, the extracellular matrix (ECM) provides an important scaffold for organs. Dysregulation of ECM in disease conditions, characterised by excess...
In a physiological context, the extracellular matrix (ECM) provides an important scaffold for organs. Dysregulation of ECM in disease conditions, characterised by excess deposition of connective tissue and extracellular matrix in response to a pathological insult, is a key driver of disease progression in multiple organs. The resultant fibrosis is predominantly an irreversible process and directly contributes to, and exacerbates, dysfunction of an affected organ. This is particularly paramount in the kidney, liver, heart and lung. A hybrid Joint Meeting of NC-IUPHAR and British Pharmacological Society was held in Paris and via a webinar in November 2020, when two successive sessions were devoted to translational advances in fibrosis as a therapeutic target. On the upsurge of response to these sessions, the concept of a special themed issue on this topic emerged, and is entitled Translational Advances in Fibrosis as a Therapeutic Target. In this special issue, we seek to provide an up-to-date account of the diverse molecular mechanisms and causal role that fibrosis plays in disease progression (contributing to, and exacerbating, dysfunction of affected organs). Recent developments in the understanding of molecular targets involved in fibrosis, and how their actions can be manipulated therapeutically, are included. LINKED ARTICLES: This article is part of a themed issue on Translational Advances in Fibrosis as a Therapeutic Target. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v180.22/issuetoc.
Topics: Humans; Heart; Extracellular Matrix; Fibrosis; Disease Progression
PubMed: 37846458
DOI: 10.1111/bph.16236 -
Internal Medicine Journal Sep 2021Vasculopathy associated with connective tissue diseases (CTD) has diverse clinical presentations and complex underlying pathology. Existing imaging techniques remain...
Vasculopathy associated with connective tissue diseases (CTD) has diverse clinical presentations and complex underlying pathology. Existing imaging techniques remain inadequate for assessing vasculopathy in CTD, particularly in earlier stages of pathogenesis. Novel imaging techniques, such as optical coherence tomography, near-infrared spectroscopy and superb microvascular imaging, demonstrate potential in monitoring disease progression at earlier stages prior to systemic complications.
Topics: Angiography; Connective Tissue Diseases; Disease Progression; Humans; Vasculitis
PubMed: 34541763
DOI: 10.1111/imj.15476